Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,874 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Renal Failure
Interventions: Group 1: Alternative Fistula, Group 2: Forearm AV Graft; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Volunteer
Interventions: NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Lincoln, Nebraska

Conditions: Juvenile Idiopathic Arthritis
Interventions: naproxen, esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions: PF-04991532, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bipolar Depression, Treatment Resistant Depression
Interventions: Intensive intermittent theta-burst stimulation (iTBS); Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depression, Mood Disorders, Major Depresssion
Interventions: Ketamine, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions: BGB-21447, Fulvestrant, BGB-43395; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Iowa City, Iowa • Houston, Texas • Seattle, Washington

Conditions: Fall Injury, Fall Patients, Mobility Limitation
Interventions: FAST Program, Otago Exercise Program; Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: TBI Depression
Interventions: Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS), Sham Comparator: Sham Treatment; Combination Product · Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hyperglycemia, Diabetes
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 3,184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteers
Interventions: LY2886721 in a Capsule, LY2886721 in an orally disintegrating tablet (ODT); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: ALXN1840, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia, Pre-leukemic Syndromes, Monosomy 7, Bone Marrow Clonal Malformations, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
Interventions: Withdrawal of immunosuppression and donor lymphocyte infusion; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Months to 25 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: San Francisco, California • St. Petersburg, Florida

Conditions: Non Hodgkin Lymphoma
Interventions: UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: David Wald; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Iowa City, Iowa • Cleveland, Ohio

Conditions: Healthy
Interventions: Midodrine HCl Tablets 5 mg, ProAmatine® Tablets 5 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection, Dietary Intervention, Fasting; Procedure · Other · Behavioral
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Homocystinuria
Interventions: SYNB1353; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Healthy
Interventions: Colchicine, Seville Orange Juice; Drug · Other
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Tobacco Dependence
Interventions: Usual care, Lung age, Contingency Management, Lung age + Contingency Management; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid Overdose Prevention, HIV Prevention and Care, Harm Reduction
Interventions: PROTECT-ED Care Coordination; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dyslipidemias
Interventions: Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 33
States / cities: Huntsville, Alabama • Encinitas, California • San Diego, California + 29 more

Conditions: Pancreatic Cancer Non-resectable
Interventions: Folfirinox, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Hypertension
Interventions: baxdrostat (formerly CIN-107) oral solution; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Randomized Fistula Study

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532

Intensive TMS for Bipolar Depression

Rapid Antidepressant Effects of Ketamine in Major Depression

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Minimizing Fall-Related Injury in Older Adults: a Motor Learning Approach

Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)

Diabetes in the Perioperative Period

A Study of Two Dosage Forms of LY2886721 in Healthy Participants

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg

A Study of Accelerated Guideline-Directed Medical Therapy for Heart Failure

Weight Loss Interventions to Reduce Cancer Progression in Prostate Cancer Patients Under Active Surveillance

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers

Drug-Food Interaction Study of Seville Orange Juice and Colchicine

A Study of Novel Smoking Cessation Interventions in Current and Former Injection Drug Users

Prevention and Rapid Outreach for Treatment, Engagement, and Care Transition From the Emergency Department

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

Baxdrostat Bioavailability and Bioequivalence Study